GlassScriptPhysician profile
Lynn M Crites
NPI 1992133979
$2,520.78
in general payments reported to CMS, 2019-2025
23 companies · $510 in 2025
The $510 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $551 · 2023: $619 · 2024: $595 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $485.56 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $282.32 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $277.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $274.38 | 2021-2025 | Freestyle Libre |
| Amgen INC. | $156.29 | 2021-2024 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.99 | 2021-2024 | Jardiance |
| Pfizer INC. | $110.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $108.70 | 2021-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Dexcom, INC. | $94.47 | 2022-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $92.84 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $89.12 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $84.27 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $83.44 | 2022-2025 | Rexulti, Abilify Maintena |
| Pharmacosmos Therapeutics INC. | $68.13 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $38.94 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $30.53 | 2022 | |
| Mylan Specialty L.P. | $16.89 | 2024 | Yupelri |
| Eisai INC. | $16.24 | 2021 | |
| Abbvie INC. | $16.12 | 2021 | |
| Lundbeck LLC | $14.16 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $3.99 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Crites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.